Arca
Skip to content
Tools
Tools

Label Changes: Acthar (corticotropin)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Acthar label DailyMed has published, from Keenova Ard LLC, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 25
  • Sections changed, version 29 to 32: 11

What changed from version 29 to version 32

Jul 22, 2026 to Oct 16, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. ContraindicationsChanged · 40 words added, 8 removed
  2. Warnings and precautionsChanged · 15 words added, 14 removed
  3. Adverse reactionsChanged · 7 words added, 1 removed
  4. Use in specific populationsChanged · punctuation or symbols only
  5. Patient counseling informationChanged · 40 words added, 21 removed
  6. Medication guideChanged · 15 words added, 47 removed
  7. Patient informationChanged · punctuation or symbols only
  8. Patient informationChanged · punctuation or symbols only
  9. Instructions for useChanged · 9 words added, 11 removed
  10. Instructions for useChanged · 9 words added, 11 removed
  11. Untitled sectionChanged · 31 words added, 25 removed

Contraindications

Changed40 words added, 8 removed
4 unchanged lines
with concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar Gel.
in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcineadrenocortical originhyperfunction.
in patients with a history of hypersensitivity reaction to corticotropin or any of the inactive ingredients of Acthar Gel or sensitivity to proteins of porcine origin. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.10)].

Warnings and precautions

Changed15 words added, 14 removed
24 unchanged lines
Prolonged use of Acthar Gel may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves and may enhance the establishment of secondary ocular infections due to fungi and viruses.
5.10 Immunogenicity Potential
5.10 Immunogenicity Potential and Hypersensitivity
Acthar Gel is immunogenic. Limited available data suggest that a patient may develop antibodies to Acthar Gel after chronic administration and loss of endogenous ACTH and Acthar Gel activity. Hypersensitivity reactions including anaphylaxis and angioedema have been reported. Prolonged administration of Acthar Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Use in patients with sensitivity to porcine protein is contraindicated, and the possibility of sensitivity should be considered during the course of treatment should symptoms arise.
5.11 Use in Patients with Hypothyroidism or Liver Cirrhosis
5 unchanged lines

Adverse reactions

Changed7 words added, 1 removed
8 unchanged lines
Ophthalmic Effects [see Warnings and Precautions (5.9)]
Immunogenicity Potential and Hypersensitivity [see Warnings and Precautions (5.10)]
Negative Effects on Growth and Physical Development [see Warnings and Precautions (5.12)]
38 unchanged lines
Allergic Reactions
Allergic responses have presented as dizziness, nausea and vomiting, skin reactions and anaphylaxis (anaphylactic shock, hypotension, respiratory compromise, urticaria, edemaangioedema).
Cardiovascular
33 unchanged lines

Use in specific populations

Changedpunctuation or symbols only
2 unchanged lines
Risk Summary
Based on Acthar Gel's pharmacological effect of stimulating an endogenous steroid response [see Clinical Pharmacology ( 12.1)], Acthar Gel may cause fetal harm when administered to a pregnant woman. The published literature on systemic corticosteroid use during pregnancy, which may be relevant, suggests potential concerns. Intrauterine growth restriction, decreased birth weight, and preterm birth have been reported with maternal use of corticosteroids; however, the underlying maternal condition may also contribute to these risks. Hypoadrenalism has also been reported in infants after high-dose and/or long-term use of corticosteroids during pregnancy (see Clinical Considerations). The potential adverse developmental effects of Acthar Gel have not been adequately assessed in animals.
The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
10 unchanged lines

Patient counseling information

Changed40 words added, 21 removed
20 unchanged lines
Inform patients, their caregivers and families that signs of irritability, sleep disturbances, mood swings, personality changes, or severe depression may occur. These effects are reversible once Acthar Gel therapy is stopped [see Warnings and Precautions (5.7) and Adverse Reactions (6.1)].
Hypersensitivity Reactions
Inform patients of the risk of hypersensitivity reactions, including anaphylaxis. Describe the symptoms of hypersensitivity reactions, including anaphylaxis, and instruct the patient to seek medical attention immediately if they experience such symptoms [see Warnings and Precautions (5.10)].
Negative Effects on Growth and Physical Development
5 unchanged lines
Pregnancy
Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations ( 8.1)].
Mallinckrodt, the "M" brand mark, SelfJect, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. © 2024 Mallinckrodt.

Medication guide

Changed15 words added, 47 removed
5 unchanged lines
Acthar Gel can cause serious side effects including:
1. Increased risk of infections. Acthar Gel is a medicine that can affect your child's immune system. When your child is taking Acthar Gel, it can lower the ability of your child's immune system to fight infections. Acthar Gel may: make your child more likely to get new infections worsen an infection that your child already has cause an inactive infection to become active, such as tuberculosis (TB) Before starting Acthar Gel, tell your doctor if your child has: an infection or signs of an infection, such as: fever cough vomiting diarrhea other signs of flu or illness a family member with an infection or signs of an infection While taking Acthar Gel, your child should: stay away from people who are sick or who have infections tell your doctor right away if your child has any sign of infection such as: fever (but your child may not have a fever with an infection) cough vomiting diarrhea or other signs of illness or flu and any open cuts or sores on his or her body
2. Effects on the adrenal gland after stopping Acthar Gel. When your child stops taking Acthar Gel, his or her body may not produce enough of a hormone called cortisol on its own (adrenal insufficiency). Your child may need to take steroid medicine to protect the body until the adrenal gland recovers and is working well again, especially to protect the body if they have surgery or trauma. Do not stop giving your child injections of Acthar Gel without talking to your doctor first. Your doctor will tell you when and how to slowly stop giving the injections to avoid serious side effects. While slowly stopping your child's injections of Acthar Gel or after you stop giving the injections, call your doctor right away if your child has any of the following: appears weak loses weight or has a decrease in appetite appears tired or lacking energy appears pale has stomach pain appears sick or is with a fever
3. Effects on the adrenal gland while taking Acthar Gel. When your child is taking Acthar Gel, his or her adrenal gland may produce too much cortisol. This can cause symptoms of Cushing's syndrome. Cushing's syndrome is more common in children who take Acthar Gel for a long time. Symptoms of Cushing's syndrome include: increased upper body fat around the neck, but not the arms and legs weight gain rounded or "moon" face thin skin, easy bruising, and stretch marks on thighs, belly and trunk slowed growth rates in children weak bones (osteoporosis) While receiving treatment with Acthar Gel other side effects can happen that are like side effects that happen due to treatment with steroid medicines. The risk of getting side effects may increase the longer your child is treated with Acthar Gel. Side effects may include: increased blood pressure. Your doctor may check your child's blood pressure during treatment. If your child's blood pressure increases, your doctor may talk with you about possible treatment choices. too much water in the body (water retention), increased amount of body salts, and low potassium in the blood. Acthar Gel may cause your child to have an increased amount of body salts and water that stays in the body, and may lower the amount of potassium in your child's blood. Follow your doctor's instructions about if you need to decrease your child's salt intake or if you need to feed your child foods high in potassium.
4. Your child should not receive certain vaccines during treatment with Acthar Gel. Your child may receive killed or inactivated vaccines while receiving Acthar Gel. Before your child receives any vaccines, talk to your doctor about which vaccines are safe for your child. Certain vaccines could cause your child to have serious side effects, or the vaccine may not be effective.
5. Hiding (masking) symptoms of other conditions or diseases. It may be more difficult for your doctor to diagnose other conditions or diseases in your child during treatment with Acthar Gel. During treatment and after treatment ends, tell your doctor if your child has: any signs or symptoms of infection. See number 1 of this section in the Medication Guide. changes in body weight bloody or black tarry stool vomiting stomach pain excessive tiredness increased thirst fast heart rate difficulty breathing
6. Stomach and intestinal problems. Acthar Gel may cause bleeding of the stomach or intestine. Your child has an increased risk for bleeding from the stomach or having a stomach ulcer. Tell your doctor if your child has any pain in the stomach area (abdominal pain), vomits blood, or has bloody or black stools.
7. Changes in mood and behavior. During treatment with Acthar Gel your child may be irritable, have rapid changes in his or her mood, be depressed, have other changes in his or her behavior, or have trouble sleeping. Tell your doctor if your child has any of the side effects or symptoms listed above.
What is Acthar Gel?
47 unchanged lines
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Acthar Gel for a condition for which it has not been prescribed. Do not give Acthar Gel to other people, even if they have the same symptoms. It may harm them.
This Medication Guide summarizes the most important information about Acthar Gel. If you would like more information, talk with your child's doctor. You can ask your child's doctor or pharmacist for information about Acthar Gel that is written for healthcare professionals. For more information, go to www.acthar.com or call 1-800-844462-28303636.
What are the ingredients in Acthar Gel?
1 unchanged line
Manufactured for:
MallinckrodtKeenova ARD LLC Bridgewater, NJ 08807
PL122 Rev 02/2024
Rev 09/2026
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Mallinckrodt, the "M" brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. © 2024 Mallinckrodt.
For a list of patents, see https://www.mallinckrodt.com/patents/
Mallinckrodt™ Pharmaceuticals
© 2026 Keenova Therapeutics plc or one of its affiliates.

Patient information

Changedpunctuation or symbols only
10 unchanged lines
3. Choose and Clean the Injection Site
For under the skin (subcutaneous) injection only. Choose 1 of these sites for injection: - Upper thigh - Belly (abdomen), not within 1-inch of belly button (navel) - Back of arm (only if someone else is giving the injection) Choose a different site for each injection. Do not inject through clothing. Avoid injecting into: - Irritated skin (red, swollen, or painful) - Tattoos, warts, scars, or birthmarks - Within 1-inch of knee or groin area - Stretch marks | | Wash your hands well with soap and water. |
Clean the injection site with an alcohol swab. |
6 unchanged lines

Patient information

Changedpunctuation or symbols only
10 unchanged lines
3. Choose and Clean the Injection Site
For under the skin (subcutaneous) injection only. Choose 1 of these sites for injection: - Upper thigh - Belly (abdomen), not within 1-inch of belly button (navel) - Back of arm (only if someone else is giving the injection) Choose a different site for each injection. Do not inject through clothing. Avoid injecting into: - Irritated skin (red, swollen, or painful) - Tattoos, warts, scars, or birthmarks - Within 1-inch of knee or groin area - Stretch marks | | Wash your hands well with soap and water. |
Clean the injection site with an alcohol swab. |
6 unchanged lines

Instructions for use

Changed9 words added, 11 removed
8 unchanged lines
Before Use | After the Injection is Complete
Storing Your Injector Store the Acthar Gel single-dose pre-filled SelfJect injector in the refrigerator between 36°F and 46°F (2°C and 8°C). Store the Acthar Gel single-dose pre-filled SelfJect injector in the original plastic tray to protect the injector from light. When it is time to use the Acthar Gel single-dose pre-filled SelfJect injector, take 1 injector from the refrigerator and return any unused injectors to the refrigerator. After removing the injector from the refrigerator, it can be stored at room temperature between 68°F and 77°F (20°C and 25°C) for up to 24 hours. If the Acthar Gel single-dose pre-filled SelfJect injector has been left at room temperature for more than 24 hours, contact MallinckrodtKeenova Therapeutics plc: 1-800-844462-28303636. Do not heat the Acthar Gel single-dose pre-filled SelfJect injector. Do not freeze the Acthar Gel single-dose pre-filled SelfJect injector. Do not put the Acthar Gel single-dose pre-filled SelfJect injector into direct sunlight. Keep the Acthar Gel single-dose pre-filled SelfJect injector and all medicines out of the reach of children.
Step 2: Prepare to Use the Acthar Gel single-dose pre-filled SelfJect injector Choose a clean, well-lit room to give the injection.
22 unchanged lines
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Manufactured for: MallinckrodtKeenova ARD LLC Bridgewater, NJ 08807
SPC-0204 Rev 8
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: 08/2024
Revised: 09/2026

Instructions for use

Changed9 words added, 11 removed
8 unchanged lines
Before Use | After the Injection is Complete
Storing Your Injector Store the Acthar Gel single-dose pre-filled SelfJect injector in the refrigerator between 36°F and 46°F (2°C and 8°C). Store the Acthar Gel single-dose pre-filled SelfJect injector in the original plastic tray to protect the injector from light. When it is time to use the Acthar Gel single-dose pre-filled SelfJect injector, take 1 injector from the refrigerator and return any unused injectors to the refrigerator. After removing the injector from the refrigerator, it can be stored at room temperature between 68°F and 77°F (20°C and 25°C) for up to 24 hours. If the Acthar Gel single-dose pre-filled SelfJect injector has been left at room temperature for more than 24 hours, contact MallinckrodtKeenova Therapeutics plc: 1-800-844462-28303636. Do not heat the Acthar Gel single-dose pre-filled SelfJect injector. Do not freeze the Acthar Gel single-dose pre-filled SelfJect injector. Do not put the Acthar Gel single-dose pre-filled SelfJect injector into direct sunlight. Keep the Acthar Gel single-dose pre-filled SelfJect injector and all medicines out of the reach of children.
Step 2: Prepare to Use the Acthar Gel single-dose pre-filled SelfJect injector Choose a clean, well-lit room to give the injection.
23 unchanged lines
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Manufactured for: MallinckrodtKeenova ARD LLC Bridgewater, NJ 08807
SPC-0205 Rev 8
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: 08/2024
Revised: 09/2026

Untitled section

Changed31 words added, 25 removed
For a list of patents, see https://www.mallinckrodt.com/patents/
Keenova, Keenova Therapeutics, Acthar, and SelfJect are trademarks of a Keenova Therapeutics plc company. © 2026 Keenova Therapeutics plc or one of its affiliates.
Manufactured for:
Manufactured for: Mallinckrodt ARD LLC Bridgewater, NJ 08807
Keenova ARD LLC Bridgewater, NJ 08807
SPC-0188 Rev 3
Mallinckrodt™ Pharmaceuticals

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Drug interactions, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton, PRINCIPAL DISPLAY PANEL - 4 x 0.5 mL Injector Carton, PRINCIPAL DISPLAY PANEL - 4 x 1.0 mL Injector Carton.

Every version

25 versions of set 7b48ddec-e815-45f4-9ca0-5c0daaf56f30, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.